All In Biotech

Drug Trial Radar · NCT01295294

Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)

International, Prospective, Double-blind, 3-arm Comparative, Randomized, Placebo-controlled Phase IV Study on the Effect of Counseling and Either Tranexamic Acid or Mefenamic Acid or Placebo, on the Management of Bleeding/Spotting in Women Using the Levonorgestrel-releasing Intrauterine System (MIRENA) for Contraception.

Last checked: Nov 20, 2026Latest source record: Nov 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 187 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

187

Actual

Start

Mar 2011

Primary completion

Dec 2011

Study completion Dec 2011

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Feb 14, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to investigate if the study drugs (tranexamic acid or mefenamic acid) can control irregular bleeding during the first 3 months of using Mirena. The study drugs tested are tested against placebo ("dummy medication not containing any active drug"). Treatment period is followed by a one-month period when study drugs are not taken but Mirena use is continued.

Conditions

  • Uterine Hemorrhage

Interventions

  • Tranexamic acidDrug

    500 mg 3 times daily per oral during bleeding/spotting episodes

  • Mefenamic acidDrug

    500 mg 3 times daily per oral during bleeding/spotting episodes

  • PlaceboDrug

    3 times daily per oral during bleeding/spotting episodes

  • Mirena (Levonorgestrel IUS, BAY86-5028)Drug

    In vitro release rate 20 microgram/24 hours. Intrauterine system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy variable will be the cumulative number of bleeding / spotting daysTime frame: During 90 day double-blind treatment period

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Aalborg, Denmark

  • Site not named

    Århus C, Denmark

  • Site not named

    København NV, Denmark

  • Site not named

    Odense C, Denmark

  • Site not named

    Skive, Denmark

  • Site not named

    Søborg, Denmark

  • Site not named

    Cork, Ireland

  • Site not named

    Mallow, Cork, Ireland

  • Site not named

    Blackrock, Dublin, Ireland

  • Site not named

    Elverum, Norway

  • Site not named

    Haugesund, Norway

  • Site not named

    Trondheim, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.